ScreenerHero

CALCCalciMedica Inc. Common Stock

NAS · US · Healthcare · Biotechnology · calcimedica.com
0.5728USD-6.57%Mkt Cap: 17.61M $P/E: —

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap17.61M $
Enterprise Value10.49M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.56M $
Revenue/Share—
Last Price0.5728 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.36
PEG—
EV/EBITDA-0.54
EV/Revenue—
P/S—
P/B3.26
EPS (TTM)-1.29
EPS (Forward)-1.63
52W Range
0.46102% of range7.200
52W High7.200 USD
52W Low0.4610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE445.14%
ROA-217.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.18M $
CapEx (TTM)28.00K $
FCF Margin—
FCF Yield-59.85%
Net Debt-9.42M $
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity-1.46
Current Ratio5.58
Quick Ratio5.33
Book Value/Sh0.1790 USD
Cash/Share0.5450 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+1645.8%
Target Range6.000 USD – 15.00 USD
$6.000+1645.8% to mean$15.00
# Analysts3
Ownership
Shares Out.30.74M
Float18.95M
Insiders18.53%
Institutions57.45%
Short Interest
Short Ratio1.4d
Short % Float2.54%
Short % Out.1.64%
Shares Short503.07K
Short (prev mo.)1.65M
Technical
SMA 500.7850 (-27.0%)
SMA 2001.864 (-69.3%)
Beta1.12
S&P 52W Chg18.16%
Avg Vol (30d)292.44K
Avg Vol (10d)322.16K
Technical Indicators
RSI (14)38.3
MACD-0.0488
MACD Signal-0.0368
MACD Hist.-0.0121
BB Upper0.8994 USD
BB Middle0.7143 USD
BB Lower0.5291 USD
BB Width51.84%
ATR (14)0.0798 USD
Vol Ratio (20d)0.86x